<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04889248</url>
  </required_header>
  <id_info>
    <org_study_id>ALS_UFV_21</org_study_id>
    <nct_id>NCT04889248</nct_id>
  </id_info>
  <brief_title>Inspiratory Muscle Training With Powerbreath Device in Patients With ALS</brief_title>
  <official_title>Inspiratory Muscle Training in Respiratory Capacity, Heart Rate Variability, Life Quality and Emotional State in Patients With Amyotrophic Lateral Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Francisco de Vitoria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Francisco de Vitoria</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abstract:&#xD;
&#xD;
      Context/background: people affected by Amyotrophic Lateral Sclerosis (ALS) see their own life&#xD;
      totally disturbed after the diagnosis. This disease also courses, apart from the functional&#xD;
      and depressing worsening, with internal damage manifested by a cardio respiratory&#xD;
      deterioration. There are not many clinical studies publications about this disease given that&#xD;
      is considered a weird illness with short prognosis.&#xD;
&#xD;
      Objectives: to examine the effects of the inspiratory muscle training (IMT) on respiratory&#xD;
      muscle strength, heart rate variability (HRV), quality of life and mood in patients with ALS.&#xD;
&#xD;
      Methods: 20 volunteer patients, male and female, with ALS, bulbar or spinal will take part of&#xD;
      the cuasi-experimental study and they will be divided into two groups: an experimental group&#xD;
      (n = 10) and a control group (n = 10). The Maximum Inspiratory Pressure (PIM), the HRV, the&#xD;
      quality of life and mood will be measured. The participants of experimental group will&#xD;
      conduct 30 inspirations per day, 15 in the morning and 15 in the evening, 5 days per week,&#xD;
      through 8 weeks. The resistance of the training in the experimental group will be increase&#xD;
      acording to the PIM measured at the first visit. During the first week, the resistance will&#xD;
      be at 30% of PImax, weeks 2 and 3 at 40%, weeks 4 and 5 at 50% and the last 3 weeks at 60%.&#xD;
      After 8 weeks, all participants will fill up again all scales and post training measurements&#xD;
      will be taken.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Actual">July 13, 2021</completion_date>
  <primary_completion_date type="Actual">May 21, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PImax</measure>
    <time_frame>8 weeks</time_frame>
    <description>Maximum Inspiratory Pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HRV</measure>
    <time_frame>8 weeks</time_frame>
    <description>Heart Rate Variability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HR</measure>
    <time_frame>8 weeks</time_frame>
    <description>Heart Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALSAQ-40</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Amyotrophic Lateral Sclerosis Assessment Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALSFRS-R</measure>
    <time_frame>8 weeks</time_frame>
    <description>ALS Functional Rating Scale Revised</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>Depression scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Treatment as usual</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Without inspiratory muscle training. Treatment as usual.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inspiratory Muscle Training with Powerbreath IMT device.</intervention_name>
    <description>Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks.&#xD;
Each day, each subject perform 15 repetitions in the morning and evening, from Monday to Friday, resting on weekends.&#xD;
The endurance of the device increases along the study, initiating with the 30% of their own maximum inspiratory pressure (PImax) during the first week and increasing a 10% every other week, till reach the goal of 60% PImax.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Subjects with ALS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PImax more than 30mmH2O&#xD;
&#xD;
          -  Score higher than 2 in GDS Reisberg scale&#xD;
&#xD;
          -  Using already respiratory devices during the day (except night CPAPs support) more&#xD;
             than 14h/day.&#xD;
&#xD;
          -  Unstable medical disease for the last 3 years.&#xD;
&#xD;
          -  Use of IMT contraindicated for medical reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Davinia Vicente Campos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Francisco de Vitoria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidad Francisco de Vitoria</name>
      <address>
        <city>Pozuelo De Alarc√≥n</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 14, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic lateral sclerosis</keyword>
  <keyword>Maximum Inspiratory Pressure</keyword>
  <keyword>Diaphragm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

